Clinical trials: Alcoholism
Alcohol Use Disorder
A Study of New Treatment for Excessive Alcohol Users by Electric Stimulation of Nerves Around Ear
Alcohol Use Disorders (AUD's) are a major health and social problem. Relapse is a rule rather than an exception in alcohol dependence, leading to poor outcomes. Craving are frequently associated with relapse.
- Trial name
- NCT04106739
- Testing
- Drug Relief V(version) 2.0 Auricular Percutaneous Electrical Neural Field Stimulation (PENFS)
- Where
- India
- Volunteers
- 44 people
- Sponsor
- DyAnsys, Inc.
Alcoholism
Clinical Study of TripleA for Treatment of Alcohol Addiction in Outpatient Care
The primary objective is to investigate differences in the alcohol consumption pattern between alcohol addicts receiving conventional treatment and those who receive a combination of conventional treatment and TripleA.
- Trial name
- NCT03195894
- Testing
- TripleA
- Volunteers
- 115 people
- Sponsor
- Kontigo Care AB
Schizophrenia, Alcohol Use Disorder
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
This double-blind, randomized study will evaluate the efficacy, safety and tolerability of ALKS 3831 in subjects with schizophrenia and alcohol use disorder (AUD).
- Trial name
- NCT02161718
- Testing
- Samidorphan + olanzapine (ALKS 3831)
- Where
- 71 sites in United States, Bulgaria and 1 more
- Volunteers
- 300 people
- Sponsor
- Alkermes, Inc.
Alcohol Use Disorder (AUD)
Sleep and Emotional Reactivity in Alcohol Use Disorder
Alcohol use disorder (AUD) is a multifaceted, chronic relapsing disorder suffered by millions of men and women in the United States.
- Trial name
- SEAS (NCT04979507)
- Testing
- Uninterrupted sleep followed by functional neuroimaging.
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- SRI International
Alcohol Dependence
A Study of MK0594 in Patients With Alcohol Dependence (0594-020)
A study in patients with alcohol dependence to see if MK0594 is safe and effective in maintaining absence of heavy drinking over a 12-week treatment period.
- Trial name
- NCT00835718
- Testing
- Comparator: MK0594 5 mg/day, Comparator: MK0594 1 mg/day, Comparator: MK0594 1 mg/week
- Volunteers
- 162 people
- Sponsor
- Vyne Therapeutics Inc.
Alcohol Abuse, Alcohol Dependence
Remote Brief Intervention and Referrals to Treatment Service for Alcohol
The traditional paradigm that relies upon training physicians and nurses or uses on-site interventionists to perform screening, brief intervention, and referral to treatment (SBIRT) for alcohol has proven unsustainable in most…
- Trial name
- RBIRT (NCT02622984)
- Testing
- RBIRT, SBIRT
- Where
- United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Polaris Health Directions
Alcohol Use Disorder
Baclocur® Post-Authorisation Safety Study in Real-life Settings in France
The overall goal of the study is to further characterize the risks and the safety profile of Baclocur® in real life settings, over a 12-month follow-up period.
- Trial name
- BACLOLIFE (NCT04679142)
- Testing
- Baclofen Tablets
- Where
- France
- Volunteers
- 975 people
- Sponsor
- Ethypharm
Hepatic Cirrhosis, Alcoholism
Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function
The purpose of this study is to evaluate the effect of varying degrees of hepatic function (Child-Pugh classification) on the pharmacokinetics and safety of pasireotide s.c. in subjects.
- Trial name
- NCT00698464
- Testing
- Pasireotide
- Where
- 4 sites in United States, Belgium and 2 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Alcohol Use Disorder (AUD), Alcohol Dependence
Evaluation of the Efficacy of Sodium Oxybate in the Long-term Maintenance of Abstinence in Alcoholic Patients
Additional pharmacotherapies in the treatment of alcohol dependence are needed. Sodium oxybate showed efficacy in the maintenance of abstinence in alcohol-dependent patients in several small randomized trials of short duration.
- Trial name
- GATE2 (NCT04648423)
- Testing
- Sodium Oxybate
- Volunteers
- 314 people
- Sponsor
- Laboratorio Farmaceutico Ct S.r.l.
Alcohol Use Disorder
Pilot Evaluation of the Empower Neuromodulation System in AUD Patients
This study evaluates the effects of peripheral nerve stimulation on alcohol craving and consumption in participants with alcohol use disorder (AUD).
- Trial name
- NCT03983317
- Testing
- Empower Neuromodulation System
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Theranova, L.L.C.
Alcohol Use Disorder
Treatment Parameters for the Empower Neuromodulation System (ENS)
The subject will be administered a treatment at a treatment location and then be asked if he/she believes it is the active treatment, sham treatment, or does not know.
- Trial name
- AUD1 (NCT03807544)
- Testing
- TENS
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Theranova, L.L.C.
Alcohol Use Disorder
Effect of GET73 on MRS Measures of Central Glutamate and GABA in Individuals With Alcohol Use Disorder
This study is aimed at examining whether GET73 modulates the indices of central glutamate and γ-aminobutyric acid (GABA) levels in recently abstinent subjects that meet Alcohol Use Disorder (AUD) criteria, as measured by proton…
- Trial name
- NCT03418623
- Testing
- GET73
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Laboratorio Farmaceutico Ct S.r.l.
Alcohol Use Disorder
Contingency Management for Alcohol Use Disorder
Randomized pilot study of a device (smartphone app) that poses non-significant risk to participants and is exempt from Investigational Device Exemption regulations [21 Code of Federal Regulations 812.2(c)
- Trial name
- NCT03701204
- Testing
- DynamiCare Rewards
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- DynamiCare Health
Alcohol Dependence
A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence
The long-term safety and efficacy of nalmefene hydrochloride at 20 mg in patients with alcohol dependence will be evaluated in a multicenter, open-label, uncontrolled trial.
- Trial name
- NCT02382276
- Testing
- Nalmefene hydrochloride
- Where
- 7 sites in Japan
- Volunteers
- 405 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Alcohol Use Disorder, Post Traumatic Stress Disorder
CCTAP: Cognitive Control Training for Treatment of AUD-PTSD
The primary objective of this study is to evaluate the feasibility of the revised brain training program with individuals diagnosed with Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD).
- Trial name
- NCT03200028
- Testing
- Computerized Plasticity-Based Adaptive Cognitive Training
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Posit Science Corporation
Alcohol Dependence
A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)
The efficacy, safety, and dose-response of nalmefene hydrochloride at 10 mg and 20 mg in patients with alcohol dependence will be evaluated in a multicenter, randomized, double-blind, placebo-controlled, 3-parallel-group…
- Trial name
- NCT02364947
- Testing
- Nalmefene hydrochloride
- Where
- 7 sites in Japan
- Volunteers
- 678 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Alcohol Dependence
A Study for the Treatment of Alcohol Dependence
The Primary objective of this study is to test whether LY2196044 can reduce the number of heavy drinking days per month in people with alcohol dependence.
- Trial name
- NCT00804570
- Testing
- LY2196044
- Where
- 17 sites in United States
- Volunteers
- 375 people
- Sponsor
- Eli Lilly and Company
Alcohol Dependence
A Study in the Treatment of Alcohol Dependence.
H8R-MC-HJAQ is a Phase 2, parallel, double-blind, randomized study comparing LY686017 with placebo in a 12-week trial that includes Medical Management.
- Trial name
- NCT00805441
- Testing
- LY686017
- Where
- 21 sites in United States
- Volunteers
- 190 people
- Sponsor
- Eli Lilly and Company
Alcohol Dependence, Alcohol Interaction
Clinical Trial to Evaluate the Safety of PT150 (Formerly ORG34517) When it is Taken Concurrently With Alcohol
The purpose of the clinical study is to compare pharmacodynamic and safety endpoints following an alcohol challenge prior to and concurrent with PT150 (study drug) treatment.
- Trial name
- NCT03548714
- Testing
- PT150, Beverage
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Pop Test Oncology LLC
Alcohol Dependence
Efficacy and Safety Evaluating Study of Odelepran for the Use in Patient With Alcohol Dependence
The purpose of this study was to assess efficacy and safety of the study drug Odelepran, 125 mg as compared to placebo in the treatment of alcohol dependence in adult outpatients.
- Trial name
- NCT03663374
- Testing
- Odelepan
- Where
- 22 sites in Kazakhstan, Russia
- Volunteers
- 644 people
- Sponsor
- R-Pharm